SCM
CTNM

Silverarc Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Silverarc Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Sell
296,135
-5,594
-2% -$73.3K 0.5% 52
2026
Q1 		$3.94M Sell
301,729
-5,811
-2% -$77.9K 0.4% 48
2025
Q4 		$3.52M Buy
307,540
+141,379
+85% +$1.61M 0.49% 47
2025
Q3 		$1.95M Buy
+166,161
New +$1.34M 0.26% 63

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Silverarc Capital Management's CTNM Position: Q2 2026 in Review

Silverarc Capital Management reduced its Contineum Therapeutics (CTNM) stake by 1.9% in Q2 2026, selling an estimated $73.3K and leaving 296,135 shares worth $4.85M. The position accounts for 0.5% of the portfolio, ranked #52.

Silverarc Capital Management first reported a position in CTNM in Q3 2025 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Silverarc Capital Management held 296,135 shares of Contineum Therapeutics worth $4.85M as of Q2 2026.
  • Silverarc Capital Management sold 5,594 Contineum Therapeutics shares in Q2 2026, an estimated $73.3K.
  • Contineum Therapeutics made up 0.5% of Silverarc Capital Management's portfolio in Q2 2026, its #52 holding.
  • Silverarc Capital Management first reported a position in Contineum Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.